NCT05468645View on ClinicalTrials.gov

In Vivo Mass Balance Study of [14C]Hemay005

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Health Volunteer
Interventions
DRUG

[14C]Hemay005

Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT05468645 - In Vivo Mass Balance Study of [14C]Hemay005 | Biotech Hunter | Biotech Hunter